PACS Group, Inc. is giving Wall Street a reason to smile, with its Salt Lake City roots, NYSE ticker PACS, and a stock that is rallying smartly today while still showing solid gains over the year despite bouts of volatility.
From the Wasatch…
GameStop (GME) is trying on a new costume: from mall-based meme stock to would‑be e‑commerce juggernaut. The company has lobbed a roughly $55–56 billion cash‑and‑stock offer for eBay (EBAY), proposing $125 per share, a premium to where eBay traded before the news hit.…
In a market where capital efficiency has become the new currency of credibility, Eli Lilly & Co. (LLY) appears to be writing a decidedly modern playbook for growth—one acquisition at a time. The Indianapolis-based pharmaceutical heavyweight has quietly assembled a portfolio of…
In a move that underscores the convergence of cloud, communications, and capital, Amazon (NASDAQ: AMZN) confirmed plans to acquire Globalstar (NYSE: GSAT) in an $11.6 billion all-cash deal. The acquisition represents Amazon’s most assertive step yet into the satellite communications sector, fortifying its ambitions to extend Project…
OpenAI’s purchase of TBPN turns a buzzy tech talk show into a strategic asset, and in the process makes the company look less like a lab and more like a network—in every sense of the word. The deal may read as “chasing…
Big Pharma spent the week shopping again, snapping up a fresh crop of biotech and pharmaceutical names in deals that underscore one message: pipelines are the new gold, and the majors are still happily paying spot prices. From autoimmune bets to allergy…
NAYA Therapeutics (https://www.nayatx.com) is quietly trying to make “next‑gen radiopharma” sound less like sci‑fi and more like standard operating procedure—and its new board lineup reads like a who’s who of oncology, nuclear medicine, and biotech capital markets.
A New Board for a…
French pharmaceutical group Servier has quietly become one of the most methodical players in oncology—and its latest move underscores that reputation. The company announced a definitive agreement to acquire Day One Biopharmaceuticals (Nasdaq: DAWN) for $21.50 per share in cash, valuing the…
Eli Lilly (LLY) has once again muscled its way to the top of the healthcare league tables, with its stock climbing as investors double down on the idea that obesity drugs are less a fad and more a new asset class. The…
IonQ’s (IONQ) decision to buy SkyWater Technology for $1.8 billion reads like a quantum-age industrial policy love story: a fast‑growing quantum upstart marries a scrappy U.S. chip foundry, and the honeymoon is scheduled right onshore. For investors, the deal is a bet…